XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma

CRM1/XPO1 expression in pancreatic adenocarcinoma correlates with survivin expression and the proliferative activity

(2018) David M. Saulino et al.   Oncotarget

Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents

(2018) Trinayan Kashyap et al.   Oncotarget

Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration

(2017) Asfar S. Azmi et al.   Oncotarget

Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma

(2016) Fabrice Jardin et al.   AMERICAN JOURNAL OF HEMATOLOGY

Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia

(2016) Preetesh Jain et al.   AMERICAN JOURNAL OF HEMATOLOGY

Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone

(2016) Irfana Muqbil et al.   CANCER LETTERS

Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer

(2016) Ying Chen et al.   CLINICAL CANCER RESEARCH

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

(2016) Albiruni R. Abdul Razak et al.   JOURNAL OF CLINICAL ONCOLOGY

Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor

(2016) Tingyu Wu et al.   MOLECULAR CANCER THERAPEUTICS

RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4

(2016) Marie K. Kirby et al.   Molecular Oncology

Genomic analyses identify molecular subtypes of pancreatic cancer

(2016) Peter Bailey et al.   NATURE

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death

(2016) Trinayan Kashyap et al.   Oncotarget

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma

(2016) Robert Nakayama et al.   Oncotarget

KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models

(2015) Giovanni Luca Gravina et al.   BMC CANCER

Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells

(2015) Mingshan Niu et al.   CANCER BIOLOGY & THERAPY

Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling

(2015) F. Conforti et al.   CLINICAL CANCER RESEARCH

Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer

(2015) S. Kazim et al.   MOLECULAR CANCER THERAPEUTICS

Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma

(2015) Richard A Moffitt et al.   NATURE GENETICS

RNA Export through the NPC in Eukaryotes

(2015) Masumi Okamura et al.   Genes

Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma

(2015) Dung-Tsa Chen et al.   PLoS One

Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer

(2015) Jiankun Gao et al.   Oncotarget

KPT-330 has antitumour activity against non-small cell lung cancer

(2014) H Sun et al.   BRITISH JOURNAL OF CANCER

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

(2014) L. Rahib et al.   CANCER RESEARCH

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

SINE (selective inhibitor of nuclear export) – translational science in a new class of anti-cancer agents

(2014) John Gerecitano   Journal of Hematology & Oncology

CRM1 Is a Direct Cellular Target of the Natural Anti-cancer Agent Plumbagin

(2014) Xuejiao Liu et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Elevated expression of the nuclear export protein, Crm1 (exportin 1), associates with human oesophageal squamous cell carcinoma

(2014) PAULINE J. VAN DER WATT et al.   ONCOLOGY REPORTS

Promising SINEs for Embargoing Nuclear-Cytoplasmic Export as an Anticancer Strategy

(2014) D. S. P. Tan et al.   Cancer Discovery

Prognostic impact and targeting of CRM1 in acute myeloid leukemia

(2013) K. Kojima et al.   BLOOD

Integration of Metabolomics and Transcriptomics Revealed a Fatty Acid Network Exerting Growth Inhibitory Effects in Human Pancreatic Cancer

(2013) G. Zhang et al.   CLINICAL CANCER RESEARCH

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

(2013) Y-T Tai et al.   LEUKEMIA

CRM1 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas

(2013) Fang Zhou et al.   MEDICAL ONCOLOGY

CRM1 Is a Cellular Target of Curcumin: New Insights for the Myriad of Biological Effects of an Ancient Spice

(2013) Mingshan Niu et al.   TRAFFIC

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

(2012) R. Lapalombella et al.   BLOOD

Improving survival following surgery for pancreatic ductal adenocarcinoma – A ten-year experience

(2012) D. Hoem et al.   EJSO

Selective Inhibitors of Nuclear Export Block Pancreatic Cancer Cell Proliferation and Reduce Tumor Growth in Mice

(2012) Asfar S. Azmi et al.   GASTROENTEROLOGY

Molecular markers associated with outcome and metastasis in human pancreatic cancer

(2012) Anke Van den Broeck et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Outcomes following resection of pancreatic cancer

(2012) Elan R. Witkowski et al.   JOURNAL OF SURGICAL ONCOLOGY

Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells

(2012) J Etchin et al.   LEUKEMIA

DPEP1 Inhibits Tumor Cell Invasiveness, Enhances Chemosensitivity and Predicts Clinical Outcome in Pancreatic Ductal Adenocarcinoma

(2012) Geng Zhang et al.   PLoS One

CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity

(2011) K. Sakakibara et al.   BLOOD

Genome profiling of pancreatic adenocarcinoma

(2011) David J. Birnbaum et al.   GENES CHROMOSOMES & CANCER

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

(2011) Eric A Collisson et al.   NATURE MEDICINE

A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic Ductal Adenocarcinoma

(2010) Jeran K. Stratford et al.   PLOS MEDICINE

EXPRESSION OF CRM1 IN HUMAN GLIOMAS AND ITS SIGNIFICANCE IN P27 EXPRESSION AND CLINICAL PROGNOSIS

(2009) Aiguo Shen et al.   NEUROSURGERY

Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: Structure–activity relationship and mechanism of action

(2008) Tine Van Neck et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer

(2008) Aurelia Noske et al.   CANCER

The Karyopherin proteins, Crm1 and Karyopherin β1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation

(2008) Pauline J. van der Watt et al.   INTERNATIONAL JOURNAL OF CANCER

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

(2008) S. Jones et al.   SCIENCE

Genomic Profiling Identifies GATA6 as a Candidate Oncogene Amplified in Pancreatobiliary Cancer

(2008) Kevin A. Kwei et al.   PLoS Genetics